Discover innovative human genetic solutions to shorten the path to clinic
With the world gripped in a global pandemic ESHG, like many other scientific meetings, has gone online. Join us at the virtual ESHG 2020.2 on 6th-9th June at our live corporate satellite and in the Company Corner to learn about the latest innovative human genetic solutions.
Enabling researchers to drive towards advances in human genetics will lead to new molecular insights for future targeted therapeutics and the prevention of human disease, like the current SARS-CoV-2 pandemic. Discover more of these advances during the corporate satellite and in the Company Corner.
Live Corporate Satellite Meeting ‘Genomics into the Clinic’
Join our live online corporate satellite meeting to hear from scientific thought leaders how they pioneer the path from discovery to clinic where a comprehensive multi-omics approach can improve patient outcomes.
Date: Monday, 8th June 2020
Time: 12:00 – 13:00 CEST / 11:00 – 12:00 BST
Dr. Luca Quagliata, Senior Director of Medical Affairs, Thermo Fisher Scientific
We’ve made it to our mission to help our customers make the world healthier, cleaner and safer; especially in today’s pandemic with COVID-19 spreading across the globe leaving devastating effects. We’ll be sharing our latest innovations developed in partnership with our customers to accelerate human genetic research, solving complex challenges, fuelled by changing the paradigm of how diseases are diagnosed and treated.
Dr. José Luis Costa, Affiliated Researcher of Genetic Dynamics of Cancer Cells, Ipatimup, Portugal
The RASopathies are a class of developmental disorders caused by germline mutations in several genes that encode components or regulators of the Ras/MAPK pathway. Taken together, these disorders are one of the largest known groups of malformation syndromes, affecting approximately 1 in 1,000 individuals. The diagnosis of such disorders is particularly difficult to perform in utero and in the first years of life, as most features manifest later during childhood. Therefore, molecular analysis has become an important key for the verification of clinical research and represents a highly informative prognostic tool. Here we test the Ion Torrent Genexus System in combination with a custom designed Ion AmpliSeq gene panel to research RASopathies both in pre-natal and post-natal settings.
Prof. Carl S. Goodyear, Professor of Translational Immunology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
Rheumatoid arthritis is the commonest autoimmune inflammatory polyarthritis; causing pain, stiffness and disability, and is associated with significant co-morbidity and premature mortality. Current therapies have made a substantial impact on patient well-being, but few attain low disease activity or clinical remission. With the ability to evaluate the TCR and BCR repertoire via NGS, it is now possible to characterise unique attributes of immune response associated with this disease. With this comes the potential of novel biomarker discovery for disease stratification and therapeutic targets, including those caused by infectious agents like SARS-CoV-2.
Richard Pither, PhD, CEO, Cytox Ltd., Oxford, UK
The development of diagnostic tools to identify Alzheimer’s Disease (AD) risk at the early, pre-symptomatic stages is essential in the selection of subjects for clinical trials and ultimately, for optimising clinical intervention. The utility of Polygenic Risk Score (PRS) is gaining attention for estimating individual genetic risk and disease risk prediction in AD. Cytox, in collaboration with Cardiff University, are developing leading PRS algorithms into SNPfitRTM, a proprietary analytical software platform to enable an understanding genetic risk at the earliest stages.
Continue your exploration in the Company Corner where you can browse, learn what’s new from Thermo Fisher Scientific and chat with us directly about your genetic research needs – all from the comfort of your desk!
- The first turnkey NGS solution that automates the specimen-to-report workflow into a single day with just two user touchpoints
- SARS-CoV-2 solutions from viral research, host genetics and epidemiological studies to potential vaccine development
- Scalable workflows for high-throughput, whole-genome genotyping
- Smart real-time PCR instruments
- Whole-genome genotyping innovation for complex traits
- Reproductive health solutions from carrier screening, to high throughput CMA for pre and postnatal analysis
- Sample preparation and sequencing library solutions for optimal data generation
To join the satellite meeting and Company Corner you need to be registered to attend ESHG 2020.2 Register at 2020.eshg.org
For Research Use Only. Not for use in diagnostic procedures.